Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson B Rodrigues

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Journal of Psychiatric Research|March 11, 2021
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic reviewJoshua D Di Vincenzo, Ashley Siegel, Orly Lipsitz, et al.
Advances in Therapy|April 30, 2021
Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant DepressionEric P McMullen, Yena Lee, Orly Lipsitz, et al.
Expert Opinion on Drug Safety|June 17, 2020
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Expert Review of Neurotherapeutics|September 21, 2020
The emerging role of psilocybin and MDMA in the treatment of mental illnessHartej Gill, Barjot Gill, David Chen-Li, et al.
Journal of Affective Disorders|September 3, 2020
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Journal of Psychopharmacology (Oxford, England)|May 17, 2023
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youthNoah Chisamore, Kevork Danayan, Nelson B Rodrigues, et al.
Psychiatry Research|December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellenceJoshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Psychiatry Research|July 10, 2021
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemicJoshua D Rosenblat, Orly Lipsitz, Joshua D Di Vincenzo, et al.
Psychiatry Research. Neuroimaging|January 28, 2023
Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesityHartej Gill, Roger S McIntyre, Colin Hawco, et al.
Journal of Affective Disorders|January 10, 2021
Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Journal of Psychiatric Research|March 11, 2021
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic reviewJoshua D Di Vincenzo, Ashley Siegel, Orly Lipsitz, et al.
Advances in Therapy|April 30, 2021
Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant DepressionEric P McMullen, Yena Lee, Orly Lipsitz, et al.
Expert Opinion on Drug Safety|June 17, 2020
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Expert Review of Neurotherapeutics|September 21, 2020
The emerging role of psilocybin and MDMA in the treatment of mental illnessHartej Gill, Barjot Gill, David Chen-Li, et al.
Journal of Affective Disorders|September 3, 2020
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Journal of Psychopharmacology (Oxford, England)|May 17, 2023
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youthNoah Chisamore, Kevork Danayan, Nelson B Rodrigues, et al.
Psychiatry Research|December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellenceJoshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Psychiatry Research|July 10, 2021
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemicJoshua D Rosenblat, Orly Lipsitz, Joshua D Di Vincenzo, et al.
Psychiatry Research. Neuroimaging|January 28, 2023
Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesityHartej Gill, Roger S McIntyre, Colin Hawco, et al.
Journal of Affective Disorders|January 10, 2021
Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Pageof 7